Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220649 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
A Phase 1 study of Pancreatic Neoplasms, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00220649 is a Phase 1 study of Pancreatic Neoplasms that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 25 participants, below the 601-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00220649, a Phase 1 study of Pancreatic Neoplasms, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with metastatic solid tumors or adenocarcinoma of the pancreas.
Conditions Studied
Interventions
- DRUG gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
Study Locations (1)
New York
- St. Luke's-Roosevelt Hospital Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220649
The ClinicalTrials.gov registry entry for NCT00220649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 601-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin is the first listed.
NCT00220649 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00220649 about?
NCT00220649 is a clinical study titled "Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas". The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with metastatic solid tumors or adenocarcinoma of the pancreas.
What is the current status of trial NCT00220649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-03.
What conditions does trial NCT00220649 study?
This clinical trial studies the following conditions: Pancreatic Neoplasms.
What interventions are being tested in trial NCT00220649?
The interventions under investigation include: gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00220649?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00220649 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
-
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.